Covid 19 Clinical Trials

	Name (Synonyms)	Correlation
D007249	Inflammation NIH	0.45
D013577	Syndrome NIH	0.15
D011014	Pneumonia NIH	0.08
D045169	Severe Acute Respiratory Syndrome NIH	0.07
D018352	Coronavirus Infections NIH	0.06

Correlated HPO Terms (1)

	Name (Synonyms)	Correlation
HP:0002090	Pneumonia HPO	0.15

There is one clinical trial.

Clinical Trials

1 Randomized Trial Evaluating Effect of Outpatient Hydroxychloroquine on Reducing Hospital Admissions in Pregnant Women With SARS-CoV-2 Infection: HyPreC Trial

COVID-19 was declared a pandemic on March 11th. Efforts to save lives are essential as we will face increasing morbidity with rising demands on health care resources. Since pregnant women with COVID-19 have systematically been excluded from drug trials, potential treatment options for these high-risk individuals remain untested. The aim of our trial is to determine whether hydroxychloroquine given to COVID-19 positive pregnant women can reduce COVID-19-related hospital admissions, thereby allowing women to stay at home while limiting utilization of hospital resources and resulting exposure of health care providers.

NCT04354441 COVID-19 SARS-CoV-2 Pregnant Women Hydroxychloroquine Drug: hydroxychloroquine sulfate 200 MG Drug: Placebo oral tablet

Primary Outcomes

Description: COVID-19-related hospital admissions will be reported by the participants throughout pregnancy until delivery.

Measure: COVID-19-related hospital admissions

Time: Hospital Admission at any point from study enrollment to delivery

Secondary Outcomes

Description: Measurement of reported symptoms using a validated questionnaire on Day 3, 7, 10, and every 2 weeks. The FLU-PRO Questionnaire instructs respondents to rate the severity of 37 influenza symptoms over the past 24 hours, including those related to the nose, throat, eye, chest, head, stomach, fatigue, and body aches/pains. For 32 of 37 items, respondents rated the severity of each symptom on 5-point Likert-type scales from 0 ("Not at all), 1 ("A little bit"), 2 ("Somewhat"), 3 ("Quite a bit"), to 4 ("Very much"). For the five remaining items, severity is expressed as frequency of occurrence: vomiting or diarrhea (0 times, 1 time, 2 times, 3 times, or 4 or more times), and sneezing, coughing, and coughed up mucus or phlegm on a scale from 0 ("Never") to 4 ("Always"), with higher scores indicating more severe symptoms.

Measure: Symptoms related to COVID-19 infection

Time: Participants will be contacted at day 3, 7, and 10 post-randomization, and every 2 weeks up to to delivery

Description: Side effects related to hydroxychloqoruine

Measure: Adverse Events

Time: Participants will be contacted at day 3, 7, and 10 post-randomization, and every 2 weeks up to to delivery

Description: Type of delivery (elective non-urgent cesarean, elective urgent cesarean section, non-elective cesarean within labor, instrumental vaginal, spontaneous vaginal)

Measure: Maternal outcomes

Time: Participants will be contacted within 2 weeks after delivery to obtain information about their labor and delivery.

Description: If had cesarean delivery, indication for cesarean section

Measure: Maternal outcomes

Time: Participants will be contacted within 2 weeks after delivery to obtain information about their labor and delivery.

Description: Miscarriage or stillbirth (Yes/No)

Measure: Maternal outcomes

Time: Participants will be contacted within 2 weeks after delivery to obtain information about their labor and delivery.

Description: Labor induction or augmentation (Yes/No) and indication

Measure: Maternal outcomes

Time: Participants will be contacted within 2 weeks after delivery to obtain information about their labor and delivery.

Description: Epidural use (Yes/No)

Measure: Maternal outcomes

Time: Participants will be contacted within 2 weeks after delivery to obtain information about their labor and delivery.

Description: Gestational age at delivery (weeks)

Measure: Newborn outcomes